Bevifibatide: First Approval

DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Simon Fung is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.Additional information about this Adis Drug Review can be found here.AbstractBevifibatide (贝塔宁®; BETAGRIN®; batifiban) is a cyclic heptapeptide antagonist of glycoprotein IIb/IIIa (GP IIb/IIa; αIIbβ3 integrin receptor) and the αvβ3 integrin receptor. It was developed by Bio-Thera Solutions for the treatment of patients with acute coronary syndrome (ACS) that require percutaneous coronary intervention (PCI). On 25 June 2024, bevifibatide received approval in China for the treatment of patients with a clear diagnosis of ACS who need PCI (including coronary stenting) to reduce the risk of acute occlusion, stent thrombosis, no reflow and slow blood flow. Its first approval is as an add-on to treatment with PCI, antiplatelet and anticoagulant therapies. This article summarizes the milestones in the development of bevifibatide leading to its first approval for reducing the risk of acute occlusion, stent thrombosis, no reflow and slow blood flow in patients with ACS that requires PCI (including coronary stenting).© Springer Nature Switzerland AG 2026